2. Search Result
Search Result
Results for "

acute coronary syndrome

" in MedChemExpress (MCE) Product Catalog:

15

阻害剤およびアゴニスト

3

ペプチド

1

天然物

製品番号 製品名 Target 研究分野 構造式
  • HY-P4153
    Enlicitide chloride

    MK-0616 chloride

    		 PCSK9 Cardiovascular Disease
    Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .
    Enlicitide chloride
  • HY-109509
    Enoxaparin
    1 Publications Verification

    PK 10169; Enoxaparin sodium

    		 Factor Xa Thrombin SARS-CoV Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19 .
    Enoxaparin
  • HY-125053A
    Batifiban TFA

    		Glycoprotein VI Cardiovascular Disease
    Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .
    Batifiban TFA
  • HY-157639A
    18:2 Lyso PA sodium

    		Others Cardiovascular Disease
    18:2 Lyso PA sodium is an unsaturated lysophosphatidic acid (LysoPA), a lipid mediator mainly present in plasma and thought to be involved in the pathogenesis of acute coronary syndrome (ACS). 18:2 Lyso PA sodium significantly correlates with serum autotaxin (ATX) in peripheral arteries .
    18:2 Lyso PA sodium
  • HY-W749980A
    cis-Coronaric acid

    cis-9,10-Epoxy-12(Z)-octadecenoic acid

    		 Endogenous Metabolite Others
    cis-Coronaric acid is the 9,10-cis epoxide of linoleic acid, generated by neutrophils during the oxidative burst. It has been recovered from the lungs of hyperoxic rats and from humans with acute respiratory distress syndrome. Mitochondrial dysfunction is the main feature of cis-Coronaric acid cytotoxicity, which may be due to the diol metabolites as well as the parent epoxide.
    cis-Coronaric acid
  • HY-111348
    Lamifiban

    Ro 44-9883

    		 Integrin Cardiovascular Disease
    Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes .
    Lamifiban
  • HY-111348A
    Lamifiban TFA

    		Integrin Cardiovascular Disease
    Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes .
    Lamifiban TFA
  • HY-125053
    Batifiban

    		Integrin Cardiovascular Disease
    Batifiban, a cyclic peptide, is a platelet glycoprotein GPⅡb/Ⅲa antagonist, and inhibits platelet aggregation. Batifiban blocks circulating vitronectin binding to integrin ανβ3, Batifiban can be used for research of acute coronary syndromes .
    Batifiban
  • HY-10313
    ZD 2486

    		Integrin Cardiovascular Disease
    ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. ZD 2486 inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptor on platelets. ZD 2486 can be used for the study of conditions related to unwanted platelet aggregation, such as acute coronary syndrome, unstable angina pectoris, acute myocardial infarction, and complications from cardiovascular interventional procedures [1]
    ZD 2486
  • HY-76409
    Otamixaban hydrochloride

    FXV673 hydrochloride

    		 Factor Xa Inflammation/Immunology
    Otamixaban (FXV673) is a potent, selective, rapid-acting, competitive, and reversible fXa inhibitor (Ki=0.5 nM) that effectively inhibits both free and prothrombinase-bound fXa .
    Otamixaban hydrochloride
  • HY-117135
    HNS-32

    		Sodium Channel Calcium Channel PKC Cardiovascular Disease
    HNS-32 is a compound with antiarrhythmic and vasodilatory effects in canine hearts, showing superior protective effects against ischemic and reperfusion arrhythmias compared to an equivalent dose of Mexiletine hydrochloride (HY-A0093). Furthermore, HNS-32 exhibits significant negative chronotropic effects on mammalian ventricular myocardium, indicating its potential application value in the study of acute coronary syndrome .
    HNS-32
  • HY-182012
    DT-678

    		Drug Derivative Cardiovascular Disease
    DT-678 is an orally active antiplatelet and antithrombotic inhibitor. DT-678 is a conjugate formed by linking the active metabolite of Clopidogrel (HY-15283) with 3-nitropyridine-2-thiol via a mixed disulfide bond. DT-678 does not rely on CYP2C19 for activation, and directly releases active substances via thiol exchange reactions in vivo, exhibiting superior efficacy over Clopidogrel. DT-678 can be used in research related to acute coronary syndrome and thrombosis .
    DT-678
  • HY-W879508
    ALT-2074

    BXT-51072

    		 Cytochrome P450 Glutathione Peroxidase Inflammation/Immunology
    ALT-2074 (BXT-51071) is an orally active catalytic analogue of glutathione peroxidase. ALT-2074 is an inhibitor of human CYP3A, with its IC50 value ranging from 2.0 to 2.6 μM. ALT-2074 shows only a weak inhibitory effect on CYP3A in vivo, suggesting that it may not significantly affect the metabolism of CYP3A substrate drugs. ALT-2074 can be used to study inflammatory diseases characterized by reactive oxygen species, such as acute coronary syndrome .
    ALT-2074
  • HY-N18868
    1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine

    PC(16:0/8:0)

    		 Endogenous Metabolite Cardiovascular Disease
    1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine (PC(16:0/8:0)) is a phosphatidylcholine glycerophospholipid. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine promotes platelet aggregation and flow-induced platelet-dependent thrombus formation. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine is a valid biomarker for CAD risk, severity, and subtype differentiation. 1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine is suitable for basic research on various types of coronary artery disease .
    1-Palmitoyl-2-capryloyl-sn-glycero-3-phosphocholine
  • HY-184265
    Mito-Esculetin

    Mito-Esc

    		 Drug Derivative STAT Sirtuin AMPK PAI-1 MicroRNA Akt Mitochondrial Metabolism Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Mito-Esculetin (Mito-Esc) is an orally active mitochondria-targeted derivative of Esculetin (HY-N0284). Mito-Esculetin inhibits LPS-induced phosphorylation of STAT3 Tyr-705, partially reverses LPS-mediated depletion of SIRT3, and enhances the AMPK-SIRT1 signaling axis. Mito-Esculetin inhibits PAI-1 activity, regulates miRNA, and induces phosphorylation of IRS and AKT. Mito-Esculetin suppresses oxidant-induced endothelial dysfunction, Ang-II (HY-13948)- and high glucose-induced atherosclerotic plaque formation, Palmitate (HY-N0830)-induced insulin resistance, as well as high glucose-mediated endothelial cell senescence and inflammatory responses. Mito-Esculetin reduces body weight and non-esterified fatty acid (NEFA) levels. Mito-Esculetin can be used in research related to acute coronary syndrome, type 2 diabetes, and hyperglycemia-induced atherosclerosis .
    Mito-Esculetin

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: